Conventional treatment for cancer such as surgical resection and chemotherapy can cause damage in cases with advanced cancers. Moreover, the identification of tumor-specific targets has great importance in T-cell therapies.
plasmid into pseudo attP site in mammalian genomes (2) . PhiC31 integrase system is considered as a specific tool for gene therapy (3, 4) and transgenic research (2, 5) . The efficiency of phiC31-integrase has been indicated to be comparable with that of the widely used Cre/loxP system. Furthermore, flippase (FLP) recombinase shows only 10% recombination activity on chromosomal targets in comparison with Cre recombinase (6) . Cre and FLP cause deletion of the gene after integration (7) whereas phiC31 integrase can catalyze unidirectional and irreversible recombination between attB and pseudo attP sites (3) . Development of phiC31 integrase-based vectors for prolonged therapeutic gene expression, demonstrated that it is a robust and reliable gene delivery system (4, 8) . Sodium butyrate (NaBut) treatment increases the specific productivity of recombinant proteins in mammalian cells; but, it declines cell growth and can provoke apoptosis (9) .
NaBut inhibits the activity of many histone deacetylases, induces hyperacetylation of histones.
Histone acetylation could modify chromatin structure, lead to transcription factors and polymerases binding as well as improving gene expression (10) . Due to its impact on epigenetic mechanisms, NaBut has attracted many interest for the prevention and treatment of different diseases such as genetic/metabolic conditions and neurological degenerative disorders (11) . Valproic acid (VPA), a histone deacetylase inhibitor (HDACi), can cause impaired epigenetic modification and suppress cell growth (12) . It can increase the expression of genes that are regulated by transcription factors (13) . It has been indicated that the HDACi increases both the specific productivity and mRNA transcription level in stable CHO cell lines. Furthermore, no cellular toxicity was reported with VPA compared with other widely used HDACi such as NaBut (14) .
Blinatumumab, the most advanced bispecific T-cell engager (BiTE) with dual binding specificities (15) , arm to bind CD3+ T-cells, and an anti-CD19 arm to couple to CD19+ lymphoma cells (15) . Preclinical studies illustrated that blinatumomab's efficacy is dependent on the effector-to-target ratio and on the difference between its affinity for both CD19 and CD3 antigens (18) . In the present study, we investigated the phiC31 mediated gene integration for expression of a BiTE antibody (Blinatumomab) in CHO-DG44 cells. This is the first study in which phiC31 integrase is used for (BsAb) expression. We compared the effect of the HDAC inhibitors, NaBut and VPA on specific productivity and cell growth in stably transfected cells. The calcein-AM assay was used to determine the cytotoxic activity of the expressed monoclonal antibody (mAb). 
Materials and methods

Cell
Vector construction
The Blinatumomab sequence was cloned into the FC550A-1 (System Biosciences, USA) plasmid by EcoRV restriction enzyme. Subsequently clones containing ligated plasmid were screened with XhoI restriction enzyme. All cloning steps were done according to our previous study (19) . 6 × His-tag was introduced at the C-terminus of the construct for further detection and purification.
Cell culture
CHO-DG44 cells were grown and transfected in a chemically defined medium (Life Technologies) by using X-tremeGENE HP transfection reagent (Roche, Mannheim, Germany). They were supplemented with 8 mM L-glutamine and 1% penicillin/ streptomycin (100 μg/ml) (Invitrogen, CA, USA) in disposable vented cap flasks, at 37°C in humidified atmosphere of 5% CO 2 . Furthermore, the cells were sub-cultured every 3 days at a density of 3 × 10 5 cells/ml. Cells density and viability were determined by using Trypan blue exclusion method. 
Generation of stable cell pools
The cells were transfected in duplicates as mentioned in the previous section. Then, cells were counted and co-transfected with 3 μg of FC550A-1 donor vector (containing BsAb gene) and 1.5 μg of the helper vector (which was reported in another study) using X-treme DNA Gene HP transfection reagent (20) . FC200A-1 vector can transiently Cells were scaled up using 25 and 75 cm 3 flasks (Greiner, Belgium). The determined minimum inhibitory concentration (MIC) result for stable pool production was 4 μg/ml (Fig 1) .
Antibody purification
Based on our previous study, supernatants of the stable cell pools containing the expressed BsAb were collected to be purified by using nickel nitrilotriacetic acid (Ni-NTA) resin (QIAGEN, USA). (19) . The fraction containing the expressed antibody were collected in 1-ml tubes and stored at -20 °C.
SDS-PAGE and western blot analysis
The expressed mAb in protein level was analyzed by SDS-PAGE and western blotting. 
SDS-PAGE was
Binding activity of expressed BsAb
We used In-Cell ELISA to study the recognition of both CD3 and CD19 antigens by expressed BsAb. NALM-6 and Jurkat cell lines were utilized. A CD19/CD3 negative cell line (SK-BR-3 cell line) was used as control group. The optical density (OD) of the reactions was measured at 450 nm for each well using an ELISA plate reader (Bio-Rad, Hercules, CA) (19, 21) .
Determination of specific productivity
To calculate the specific productivity of cells, the cell pool of expressed mAb was cultured. 2×10 5 cells were seeded in shaker bottles, and viable cell density and antibody titer were evaluated during five days. Viable cell density was determined using
Trypan blue exclusion method.
Specific productivity (Qp) was measured in pg/cell/day by using the following equation (22):
Where ΔP shows the change in antibody titers (μg/ml) between the first and last days of the test, n 0 and n t indicate viable cell densities (10 6 cells/ml) in the first and last days, and t shows culture time in days.
Sodium butyrate and valproic acid treatment
To evaluate the effect of NaBut and VPA on BsAb productivity, 1 × 10 6 cell/ml were cultivated 
Statistical analysis
Obtained data were statistically analyzed in GraphPad Prism 6 software using the one-way ANOVA and t test (P value ≤ 0.05). That is to say, calcein-AM release assay was performed as technical triplicates and ELISA assay was performed in duplicates.
Results
Construction of the expression plasmid
The bispecific monoclonal antibody, Blinatumomab sequence was successfully cloned into the EcoRVsite of FC550A-1 vector.
Generation of stable cell pools using phiC31 integrase system
In this research, we used the robust phiC31 were tested for BsAb expression by SDS-PAGE and western blotting (Fig 2) . The specific bound of pg/cell/day)). NaBut treatment decreased the cell viability by 33% in comparison with control group (P<0.05), while VPA-treated cells viability was 59% which is significantly higher than NaButtreated cells (P<0.05) (Fig 4) .
Calcein-AM release assay
We tested the efficacy of BsAb at effector to target (E/T) ratios ranging from 10:1 to 2.5:1 by using purified, un-stimulated T lymphocytes as effectors and NALM-6 cells as target cells (Fig 5) .
As illustrated in Fig 6 , E/T ratios of 10:1 and 5:1 had very similar dose-response curves (P > 0.05).
Furthermore, the percentage of specific cytotoxicity was almost similar at E/T ratios of 10:1 and 5:1.
But, it was decreased at an E/T ratio of 2.5:1. The results proved that the BsAb can be effective at low E/T ratios too. The percentage of specific cytotoxicity varied from 21 to 87%. The specific cytotoxicity percentage was determined to be 87.48%, 61.14% at E/T ratios of 10:1 and 5:1, respectively. While, at an E/T ratio of 2.5:1 the extent of specific cytotoxicity decreased to 21.14%.
Thus, at E/T ratios of 10:1 and 5:1, the expressed BsAb was significantly more cytotoxic than 2.5:1 Fig. 4 . Influence of NaBut and VPA on cells specific productivity and cell viability. Stable BsAb producer cell line was cultured in the absence and presence of NaBut and VPA. Error bars indicated SD of triplicate measurements.* indicates that the differences of cell viability of NaBut and VPA treatment group were significant in comparison with control group (P < 0.05). ** indicates that the differences of cell specific productivity of NaBut and VPA treatment groups were significant in comparison with control group (P < 0.05). The difference between cell viability of NaBut treatment group and VPA treatment group was also significant (P < 0.05).
Fig. 5. Schematic of tumor cells killing by cytotoxic T cells redirected with an expressed BsAb (Blinatumomab).
4 phases were involved. The calcein AM assay was used to quantify cell viability and cytotoxicity. Fig. 6 . Dose-response curve of expressed mAb. In this experiment PBMCs from 2 donors were used. Purified T cells were incubated with NALM-6 cells at E/T ratios of 10:1, 5:1, 2.5:1 and cell lysis was determined by calcein AM release after 4 h. The test was done in triplicate.
The error bars indicate the standard deviation of two groups. The cytotoxicity observed at higher ratios than 2.5:1 was significantly higher at the concentrations higher than 1 ng/ml (P < 0.05). In order to bring down the costs of recombinant proteins production in the biopharmaceutical industry, researchers worked on regulatory principals of growth and survival during the cell culture process (29) . One strategy for increasing CHO cell productivity is the addition of HDAC inhibitors, NaBut, and VPA (29, 30) . Although, the specific productivity of NaBut was slightly more than VPA, the decrease in cell viability was remarkable in NaBut-treated group. Since VPA is an FDA-approved drug and 5-fold less expensive than NaBut, it is suggested as a cost-effective alternative to NaBut for increasing protein expression in CHO cells (24) . NaBut has been to be less effective at low E/T ratios.
